Compass, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Compass, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.96B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $5.63B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $4.89B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $6.02B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $6.42B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.72B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $2.39B | Feb 28, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.50M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($154.40M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($321.30M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($601.50M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($494.10M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($270.20M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($388.00M) | Feb 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($63.40M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($154.80M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($314.90M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($589.40M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($493.00M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($273.30M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($401.80M) | Feb 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $245.80M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $188.80M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $184.50M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $360.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $365.30M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $145.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $131.30M | Feb 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $121.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($25.90M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($291.70M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($28.60M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($58.10M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($377.00M) | Feb 28, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.40M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $15.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $11.20M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $70.10M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $50.10M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $43.30M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $74.10M | Feb 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.18B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.16B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.53B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.80B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.37B | Feb 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $752.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $765.60M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $728.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.01B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $953.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $741.30M | Feb 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $782.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $409.40M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $428.70M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $517.10M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $843.80M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($862.90M) | Feb 28, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $479.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $233.60M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $209.80M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $198.40M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $188.30M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $119.80M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $81.40M | Feb 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.73B) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($2.67B) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($2.52B) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($2.20B) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.60B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($1.10B) | Feb 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $223.80M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $166.90M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $361.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $618.30M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $440.10M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $491.70M | Feb 28, 2022 |
| FY2021 | Dec 31, 2018 | $128.60M | Feb 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 563.48M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 513.14M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 484.89M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 438.10M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 409.27M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 122.97M | Feb 28, 2022 |